MabSpace Biosciences
218 Xinghu Street
Biobay B2-609
Suzhou
215123
China
Tel: 0512-86861701
Fax: 0512-86861721
Website: http://www.mabspacebio.com/
About MabSpace Biosciences
MabSpace Biosciences, is a biotech company focused on discovery and development of innovative antibody based therapeutics for cancer and fibrotic diseases. It was founded in 2013 by indrustrial veterans and is located in Biobay Suzhou, an emerging bitech incubator in China. MabSpace employes its proprietary platform technology, immune tolerance breaking technology (IMBT), to generate lead antibodies with diverse epitopes. MabSpace has established multiple antibody discovery and co-development partnerships based on this technology. MabSpace raised 15 million USD from Lilly Asia Ventures in 2015 to advance its lead antibody program, a potentially best-in-class anti-PD-L1 antibody with unique pH-dependent binding and recycling property and significantly improved efficacy in animal models. It has also built a panel of 2nd generation immuno-oncology antibodies targeting different components of the tumor microenvironment,which enables the testing of combination therapeutic interventions with its PD-L1 antibody.YEAR FOUNDED:
2013
LEADERSHIP:
Founder and CEO: Xueming Qian
JOBS:
Please click here for MabSpace job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
6 articles about MabSpace Biosciences
-
HJB Merges with MabSpace Biosciences to Form Transcenta Holding, a Fully Integrated Leading Global Biotherapeutics Company
1/2/2019
HJB and MabSpace Biosciences today announced that the two companies have entered into a definitive merger agreement to create Transcenta Holding Ltd. (Transcenta), a world-class biotherapeutics company with fully-integrated capabilities in research, development, regulatory and manufacturing of biologics.
-
MabSpace Biosciences Doses First Patient in China Phase 1 Trial for MSB2311 and Submitted IND for MSB0254 to NMPA
9/6/2018
MabSpace Biosciences announced that on August 24th, 2018, MSB2311 was successfully administered to the first Chinese cancer patient at Beijing Cancer Hospital in its China Phase 1 trial.
-
MabSpace Biosciences Announces FDA Approval of IND for MSB2311, a Second Generation PD-L1 Antibody With pH Dependent Antigen Binding and Recycling Property
2/22/2018
MabSpace Biosciences announces on February 16th, 2018 FDA cleared Investigational New Drug (IND) for MSB2311, a humanized programmed death protein-ligand 1 (PD-L1) antibody for the treatment of patients with locally advanced/metastatic solid tumors.
-
MabSpace Biosciences Files China IND for Second-Gen PD-L1
10/27/2017
Suzhou's MabSpace Biosciences filed an IND application with the CFDA last month to begin human testing of a second-generation PD-L1 antibody.
-
MabSpace Biosciences Submits Investigational New Drug Application for Its Second Generation PD-L1 Antibody With pH-Dependent Antigen Binding Property
10/26/2017
MabSpace Biosciences announced it has filed an IND application to CFDA on September 12th, 2017 for MSB2311, a second-generation PD-L1 antibody with pH-dependent antigen binding property.
-
MabSpace Biosciences To Present Preclinical Data On Second Generation PD-L1 Antibody With pH-Dependent Antigen Binding Property At Upcoming Inaugural ASCO-SITC Clinical Immuno-Oncology Symposium
2/23/2017